Edition:
India

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
16 Aug 2019
Change (% chg)

$-0.00 (-0.08%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.64
Volume
30,156
Avg. Vol
84,897
52-wk High
$2.29
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Cti Biopharma Posts Q2 Loss Per Share Of $0.19
Friday, 2 Aug 2019 

Aug 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.19.CTI BIOPHARMA - AS OF JUNE 30, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $53.7 MILLION, COMPARED TO $67.0 MILLION AS OF DECEMBER 31, 2018.  Full Article

Cti Biopharma Q4 Earnings Per Share $0.01
Thursday, 14 Mar 2019 

CTI Biopharma Corp ::CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 EARNINGS PER SHARE $0.01.Q4 REVENUE $14.1 MILLION.AS OF DECEMBER 31, 2018, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $67.0 MILLION.EXPECTS TO MEET WITH U.S. FDA AND REPORT DETERMINATION OF AN OPTIMAL DOSE OF PACRITINIB IN MID-2019.FURTHER EXPECTS TO REPORT TOPLINE EFFICACY AND SAFETY DATA FROM PHASE 2 STUDY OF PACRITINIB BY END OF 2019.  Full Article

CTI BioPharma Announces Continuation Of PAC203 Study Following Third Interim Review
Friday, 1 Feb 2019 

Feb 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA RECEIVES RESULTS OF THE CHMP ORAL EXPLANATION FOR PACRITINIB IN THE TREATMENT OF MYELOFIBROSIS AND PROVIDES DEVELOPMENT UPDATE.CTI BIOPHARMA CORP - COMPANY ANNOUNCES CONTINUATION OF PAC203 STUDY FOLLOWING THIRD INTERIM REVIEW.CTI BIOPHARMA CORP - IDMC DID NOT IDENTIFY SIGNIFICANT DRUG- OR DOSE-RELATED SAFETY CONCERNS IN PAC203 STUDY.CTI BIOPHARMA CORP - IDMC DID NOT IDENTIFY ANY CONCERNS AROUND HEMORRHAGIC OR CARDIAC TOXICITY IN PAC203 STUDY.CTI BIOPHARMA CORP - PHASE 3 TRIAL IS EXPECTED TO BEGIN ENROLLMENT IN Q3 OF 2019.CTI BIOPHARMA CORP - PLANS TO SEEK SCIENTIFIC GUIDANCE FROM EMA BEFORE BEGINNING PLANNED PHASE 3 STUDY.CTI BIOPHARMA CORP - WILL WITHDRAW ITS EUROPEAN MARKETING AUTHORIZATION APPLICATION (MAA) FOR PACRITINIB AS A TREATMENT FOR MYELOFIBROSIS.CTI BIOPHARMA CORP - CHMP INDICATED THAT RISK-BENEFIT PROFILE FOR PACRITINIB FOR INTENDED INDICATION HAS NOT BEEN SUFFICIENTLY ESTABLISHED.  Full Article

Cti Biopharma Announces 50 Pct Reduction In Workforce Expected
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA ANNOUNCES RESTRUCTURING PLAN.CTI BIOPHARMA CORP - FIFTY PERCENT REDUCTION IN WORKFORCE EXPECTED.CTI BIOPHARMA ANNOUNCES RESTRUCTURING PLAN.CTI BIOPHARMA CORP - COST SAVINGS OF APPROXIMATELY $20 MILLION PRIMARILY ASSOCIATED WITH REDUCED EMPLOYEE COSTS ARE EXPECTED OVER THREE YEARS.CTI BIOPHARMA - PLANS TO GIVE FINANCIAL GUIDANCE IN H12019 WHEN DETAILS OF U.S. PHASE 3 TRIAL DESIGN, INCLUDING TRIAL SIZE & DOSING SCHEDULE ARE KNOWN.  Full Article

CTI Biopharma May Offer, Sell Shares Of its Common Stock
Friday, 2 Nov 2018 

Nov 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP SAYS CO MAY OFFER, SELL SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING.  Full Article

CTI Biopharma Reports Q3 Loss Per Share $0.26
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.26.PAC203 STUDY IS EXPECTED TO COMPLETE ENROLLMENT BY END OF 2018.TOP-LINE DATA FROM PAC203 STUDY EXPECTED IN Q2 OF 2019.FOLLOWING IDENTIFICATION OF OPTIMAL DOSE FROM PAC203 STUDY, CO EXPECTS TO BEGIN PHASE 3 PATIENT RECRUITMENT MID-YEAR IN 2019.AS OF SEPT 30, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $80.9 MILLION VERSUS $43.2 MILLION AS OF DEC 31, 2017.  Full Article

Cti Biopharma Q2 Loss Per Share $0.20
Thursday, 2 Aug 2018 

CTI Biopharma Corp ::CTI BIOPHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.20.  Full Article

CTI Biopharma Says Phase III Trial Evaluating Pixuvri With Rituximab In Comparison To Gemcitabine Combined With Rituximab Did Not Meet Its Primary Endpoint
Monday, 9 Jul 2018 

July 9 (Reuters) - CTI Biopharma Corp ::RESULTS OF PHASE III (PIX306) TRIAL EVALUATING PROGRESSION-FREE SURVIVAL OF PIXUVRI® (PIXANTRONE) COMBINED WITH RITUXIMAB IN PATIENTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA.CTI BIOPHARMA - PIXUVRI® PLUS RITUXIMAB DID NOT SHOW STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VERSUS GEMCITABINE PLUS RITUXIMAB.CTI BIOPHARMA - PHASE III TRIAL EVALUATING PIXUVRI WITH RITUXIMAB IN COMPARISON TO GEMCITABINE COMBINED WITH RITUXIMAB DID NOT MEET ITS PRIMARY ENDPOINT.CTI BIOPHARMA CORP - WILL PROCEED TO CONDUCT A THOROUGH REVIEW OF CLINICAL DATA TO ASSESS NEXT STEPS FOR PIXUVRI PROGRAM.  Full Article

CTI BioPharma to receive $10 mln milestone payment for Trisenox
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA TO RECEIVE $10 MILLION MILESTONE PAYMENT FOR TRISENOX®.CTI BIOPHARMA - ‍TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM TEVA PHARMACEUTICAL INDUSTRIES RELATED TO U.S. FDA APPROVAL OF TRISENOX​.  Full Article

CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​
Wednesday, 29 Nov 2017 

Nov 28 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​.CTI BIOPHARMA CORP - ‍PURSUANT TO AGREEMENT, LENDER HAS AGREED TO MAKE A SENIOR SECURED TERM LOAN OF UP TO $18 MILLION​.CTI BIOPHARMA CORP - ‍FIRST $16 MILLION OF TERM LOAN WAS FUNDED ON NOVEMBER 28, 2017​.  Full Article